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ABSTRACT: currently 250 words (250 word limit) 
Background and aims: This 11-week Phase IIa induction study evaluated the efficacy 
and safety of eldelumab in patients with active Crohn’s disease. 
Methods: Adults with Crohn’s Disease Activity Index 220–450 were randomised 1:1:1 
to placebo or eldelumab 10 or 20 mg/kg intravenously on Days 1 and 8, and alternate 
weeks thereafter. All patients underwent ileocolonoscopy at baseline. Patients with 
active inflammation according to the Simplified Endoscopic Score for Crohn’s 
Disease criterion (the originally planned endoscopy cohort) underwent another 
ileocolonoscopy at Week 11 at the investigator’s discretion. All ileocolonoscopies 
were centrally read. The primary objective was identification of the eldelumab target 
exposure for induction of remission (absolute Crohn’s Disease Activity Index score 
<150). Rates of clinical response (reduction of ≥100 from baseline or absolute score 
<150 Crohn’s Disease Activity Index), remission and endoscopic improvements were 
also assessed.  
Results: 121 patients were randomised. The eldelumab exposure–remission 
relationship was not significant at Week 11. Numerically higher remission and 
response rates were reported with eldelumab 20 mg/kg (29.3 and 41.5%, 
respectively) and 10 mg/kg (22.5 and 47.5%) versus placebo (20.0 and 35.0%). A 
higher proportion of patients with a baseline Simplified Endoscopic Score for Crohn’s 
Disease >2 who received eldemumab achieved a 50% improvement in score and 
greater reductions from baseline endoscopy scores overall versus placebo. Adverse 
events were comparable across treatment groups. 
Conclusions: No exposure–remission relationship was seen with eldelumab. 
Eldelumab induction treatment demonstrated trends towards clinical and endoscopic 
efficacy. Safety was consistent with that reported previously. ClinicalTrials.gov 
identifier: NCT01466374. 
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1. Introduction 
Crohn’s disease is a chronic inflammatory disorder of the gastrointestinal tract of 
multifactorial aetiology.1 Crohn’s disease can affect all layers of the intestinal wall, 
leading to the development of ulcers as well as the complications of fistulas and 
abscesses. This pathology manifests as symptoms such as pain, diarrhoea, vomiting 
and fatigue, and can result in a requirement for recurrent surgeries, work 
absenteeism and difficulties with interpersonal relationships.2 Crohn’s disease has a 
reported annual incidence of approximately 24 per 100,000 in Europe and 19 per 
100,000 in Northern America; incidence rates are increasing globally, particularly in 
developing countries.3 
 A number of pharmacological and surgical approaches have been developed for 
Crohn’s disease. Owing to its diverse presentation and pathophysiology, treatment 
strategies for Crohn’s disease are based on the anatomic location of the disorder, 
disease severity and therapeutic goals, such as treatment of flares and induction or 
maintenance of remission.4,5 In addition, mucosal and histological healing have 
emerged as potential treatment goals with the development of more specifically 
targeted medications and individualisation of therapeutic approaches.6,7  
 Presently, commonly used treatments for Crohn’s disease include corticosteroids, 
6-mercaptopurine (6-MP), azathioprine (AZA), methotrexate (MTX) and biologics 
(including anti-tumour necrosis factor [anti-TNF] and anti-integrin agents 
[natalizumab, vedolizumab]). These medications have a number of limitations, such 
as a lack of long-term efficacy (corticosteroids) as well as slow onset of action and 
toxicity (AZA, 6-MP and MTX). While the use of biologics represented a substantial 
development in the treatment of Crohn’s disease compared with traditional oral 
therapies, remission is achieved by as few as 20–40% of patients and maintained by 
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only 50% of these individuals at 6 months.8 Moreover, increased risks of side effects, 
including malignancies and opportunistic infections have been reported with 
biologics.9-12  
 Interferon-γ-inducible protein-10 (IP-10, also referred to as CXCL10) decreases the 
survival of gut epithelial cells and mediates trafficking of activated T cells, dendritic 
cells and monocytes to the inflamed colon.13,14 IP-10 expression by intestinal 
epithelial cells, endothelial cells and immune cells is increased in patients with 
Crohn’s disease,15,16 and reduction of IP-10 is a novel therapeutic target in Crohn’s 
disease.17,18 
 Eldelumab (BMS-936557) is a fully human monoclonal antibody that has been 
investigated as an induction and maintenance therapy in moderate to severely active 
ulcerative colitis in Phase II trials.19,20 It is hypothesised that by binding to IP-10, 
eldelumab blocks immune cell migration into the intestinal epithelium and modulates 
the impact of IP-10 on epithelial cell survival.14,21 Efficacy signals for eldelumab in the 
treatment of ulcerative colitis were observed, particularly among patients who were 
biologic naïve or receiving concomitant immunosuppressants.20 
 To date, eldelumab has not been assessed in Crohn’s disease. The induction 
period of the current Phase IIa study was designed to demonstrate dose–response 
and to evaluate the efficacy and safety of eldelumab in patients with active Crohn’s 
disease. 
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2. Materials and methods 
2.1. Study design and patients 
This Phase IIa study (ClinicalTrials.gov Identifier NCT01466374) comprised an 11-
week induction period (see online Supplementary Figure 1) and a 12-month 
exploratory maintenance period. The results of the maintenance period are not yet 
available and will be reported in a future publication. The study was conducted at 28 
sites in seven countries (Belgium, France, Hungary, Israel, Poland, South Africa and 
the USA) between 15 December 2011 and 3 November 2014. All patients gave 
written, informed consent and the study was approved by local ethics committees 
and conducted in accordance with Good Clinical Practice guidelines and the 
Declaration of Helsinki.  
Eligible patients were ≥18 years of age with moderate to severely active Crohn’s 
disease (Crohn’s Disease Activity Index [CDAI] score ≥220 and ≤450) and disease 
duration of more than 3 months. The diagnosis of Crohn’s disease was confirmed by 
radiological, endoscopic or histological evidence in the 12 months before screening; 
if a previous diagnosis had not been made or was deemed inconclusive, diagnosis 
was confirmed during the screening ileocolonoscopy. In addition, patients included in 
the trial were required to have active inflammation, indicated by high-sensitivity C-
reactive protein (hsCRP) ≥5 mg/L, or faecal calprotectin >250 µg/g, or a score of 2–3 
on the ulcerated surface subscore of the Simplified Endoscopic Score for Crohn’s 
Disease (SES-CD) in at least one of five segments during ileocolonoscopy. 
Ileocolonoscopy videos were collected from all included patients at baseline. It was 
originally planned that the endoscopy cohort would include only patients with an 
ulceration score of 2–3 in at least one of five bowel segments at baseline but, owing 
to the small sample size that resulted from this criterion, the endoscopy cohort 
definition was amended to include patients with a total SES-CD score >2. Patients 
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with active inflammation according to the SES-CD criterion (the originally planned 
endoscopy cohort) underwent another endoscopy at Week 11 at the investigator’s 
discretion. All endoscopies were read in a blinded fashion by a central reader. 
To be included in the trial, patients also had to have had an insufficient response or 
intolerance to one or more of oral prednisone (≥40 mg/day for ≥2 weeks or ≥20 
mg/day for ≥4 weeks) or budesonide (≥9 mg/day for ≥2 weeks or ≥3 mg/day for ≥4 
weeks), AZA (≥2 mg/kg/day or a therapeutic level of 6-thioguanine [6-TGN]), 6-MP 
(≥1 mg/kg/day or therapeutic level of 6-TGN), MTX (≥15 mg/week) and/or a biologic 
(anti-TNF or natalizumab; at the approved dose). 
Key exclusion criteria were a diagnosis of ulcerative colitis or indeterminate colitis, 
and a diagnosis of Crohn’s disease without colonic or ileal involvement. Patients 
were also excluded if they were suspected of having or had been diagnosed with an 
intra-abdominal or perianal abscess at screening or had known strictures or stenosis 
(without an inflammatory component, leading to symptoms of obstruction). In 
addition, patients were excluded if they had a current requirement for colostomy, 
ileostomy or total parenteral nutrition, or had previously undergone total 
proctocolectomy or subtotal colectomy with ileorectal anastomosis. Surgical bowel 
resection within 6 months of screening, extensive small bowel resection, known short 
bowel syndrome or previous sclerosing cholangitis were also reasons for study 
exclusion. In an amendment half way through the study, patients who experienced 
inadequate response/intolerance to ≥3 approved biologics were also excluded. The 
use of biologics, tacrolimus, cyclosporine, mycophenolate mofetil, D-penicillamine, 
leflunomide or thalidomide was prohibited within 8 weeks prior to randomisation; use 
of rituximab was prohibited within 1 year of randomisation. 
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2.2. Dose selection and randomisation 
Based on earlier studies of eldelumab in patients with ulcerative colitis, the 10 and 20 
mg/kg doses selected for the induction period in the present study were expected to 
generate a robust exposure–response relationship.19,20 The eldelumab 10 mg/kg 
dose did not demonstrate consistent efficacy in patients with ulcerative colitis; 
however, as the present Phase IIa study in Crohn’s disease was a dose-ranging 
study, and because Crohn’s disease is thought to have a lower inflammatory burden 
compared with ulcerative colitis, the lower dose of 10 mg/kg was deemed to be 
appropriate for inclusion.  
 During the induction period, eligible patients were randomised 1:1:1 to double-blind 
treatment with eldelumab 10 mg/kg or 20 mg/kg or placebo saline solution. 
Randomisation was stratified according to patients’ prior inadequate response and/or 
intolerance to approved biologic therapy (yes/no). Study medication was 
administered via intravenous (IV) infusion on Days 1 and 8, and every other week 
thereafter to Day 64. Adverse events (AEs) and vital signs were monitored after 
completion of infusion; initial observations of infusion reaction associated with an 
infusion time of 90 minutes resulted in a protocol amendment that extended the 
study-drug infusion to 3 hours to reduce the occurrence of infusion reactions. 
2.3. Efficacy objectives and assessments 
2.3.1. Primary objective 
The primary objective was to identify the efficacious target exposure (observed 
minimum steady-state plasma drug concentration [Cminss
]) for induction. The primary 
efficacy objective was assessment of eldelumab induction of clinical remission (CDAI 
<150) as determined by a relationship between eldelumab exposure (Cminss) and 
remission at Week 11.  
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2.3.2. Secondary and exploratory objectives 
Secondary objectives were assessment of clinical response (reduction in CDAI ≥100 
points from baseline or absolute CDAI score <150) at Weeks 7 and 11, and clinical 
remission at Weeks 7 and 11.  
 A number of exploratory objectives were also assessed during the induction period, 
including endoscopic response at Week 11 in patients in the endoscopy cohort 
(defined as ≥50% improvement in the SES-CD22); change from baseline in 
biomarkers, including hsCRP and faecal calprotectin; and the pharmacokinetics of 
eldelumab. Subgroup analyses of clinical response and remission in patients with 
prior insufficient response/intolerance to biologics or patients who were biologic naïve 
were also assessed. A number of composite endpoints (incorporating both 
symptomatic and endoscopic findings) were also investigated, including the 
percentages of patients achieving ≥30% decrease in stool frequency and abdominal 
pain alongside a 3-point decrease in SES-CD or an absolute SES-CD of zero.23  
2.3.3. Post hoc analyses 
Several post hoc analyses were performed in the endoscopy cohort for subgroups 
with baseline SES-CD score >2, ≥4 and ≥6. These analyses included an assessment 
of endoscopic response at Week 11, and the percentages of patients achieving 
≥30% decrease in stool frequency and abdominal pain and a 3-point decrease in 
SES-CD or an absolute SES-CD of zero. 
2.3.4. Efficacy assessments 
The CDAI total score is the sum of eight components with different weighting 
factors24-26; e.g. haematocrit of <0.47 units in men and <0.42 units in women has a 
weighting factor of x6. Lower scores on the CDAI indicate milder disease; severe 
Crohn’s disease is defined as a CDAI score of >450.24,26 CDAI diaries were 
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completed by patients for 7 days before each study visit (baseline and Weeks 1, 3, 5, 
7, 9 and 11) to allow investigational staff to calculate CDAI scores. 
 Changes from baseline in endoscopy score and endoscopic response were 
assessed at Week 11 using centrally read ileocolonoscopy. The SES-CD score 
comprises four variables (ulcer size, ulcerated surface area, proportion of the 
affected surface with other lesions and stenosis), scored from 0 (absence of variable) 
to 3 (most severe manifestation of variable), with the total score consisting of the sum 
of the four variables for each of the five bowel segments.27  
 Blood for assessment of hsCRP was drawn at baseline and at Weeks 1, 3, 5, 7 and 
11. Patients were required to bring stool samples to office visits for assessment of 
faecal calprotectin at baseline and Weeks 7 and 11.  
2.3.5. Pharmacokinetic assessments 
Venous blood samples for serum pharmacokinetic analyses were collected from all 
patients in this study at baseline, and at Weeks 1, 3, 5, 7 and 11. Pharmacokinetic 
analyses of eldelumab in human serum were performed using enzyme-linked 
immunosorbent assays. 
2.4. Safety assessments 
The incidence and severity of AEs were monitored throughout the study and for up to 
56 days after the last dose of study medication. Treatment-related AEs were defined 
as those possibly, probably or definitely related to the study drug; when details were 
missing, AEs were presumed to be related to treatment. Acute infusion reactions 
were defined as any AE that could potentially constitute a reaction to infusion, 
occurring within 1 hour of infusion completion.  
2.5. Statistical analysis 
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The sample sizes in this study were calculated to provide adequate power for the 
primary analysis during the induction period (logistic regression modelling to 
investigate the eldelumab exposure–response [i.e. remission] relationship at Week 
11). Based on an assumed placebo remission rate of 15%, it was calculated that to 
detect an odds ratio (OR) of 2.5 using logistic regression, 40 patients per arm were 
required to provide 90% power for a one-sided test at α = 0.05.  
 The intent-to-treat population was the primary study population, comprising all 
patients randomised and administered any study medication. The safety analysis 
was performed using the safety population, and comprised all patients who received 
at least one dose of any study medication.  
 Sequential testing was performed as a multiplicity adjustment; if the primary 
endpoint was not statistically significant then secondary endpoints were not analysed 
further. As such, the study was powered only to assess the eldelumab exposure–
remission relationship and was not statistically powered to test the efficacy 
objectives. Baseline demographics and clinical characteristics at randomisation were 
analysed descriptively. The exposure–remission relationship at Week 11 was 
modeled by logistic regression with the observed Cminss as an independent variable. 
The efficacious target exposure for induction of remission, corresponding OR and 
90% confidence interval (CI) were calculated. All patients who discontinued 
prematurely were considered to be non-responders/non-remitters in binary analyses 
in this study.  
 For the statistical analyses of secondary (efficacy) objectives, the percentage of 
patients who were responders/remitters was analysed using the Cochran–Mantel–
Haenszel chi-square test at a one-sided 5% significance level, stratified by prior 
inadequate response to/intolerance of biologics (yes/no); relative risk and 90% CIs 
were also calculated.  
14 
 
 
3. Results 
3.1. Patient disposition and demographic characteristics 
During the induction period, a total of 121 patients were randomised and treated (see 
online Supplementary Figure 2). Overall, 80.0, 85.4 and 97.5% of patients completed 
the study in the eldelumab 10 and 20 mg/kg and placebo groups, respectively. AEs 
were the reason for discontinuation in five patients in each of the eldelumab 10 and 
20 mg/kg arms (12.5 and 12.2% of patients, respectively) and no patients in the 
placebo arm. AEs leading to discontinuation included: four hypersensitivity reactions 
(two of which were serious, all occurred in the eldelumab 20 mg/kg arm); two infusion 
reactions (one each in the eldelumab 10 and 20 mg/kg arms); two serious AEs of 
exacerbation of Crohn’s disease (both in the eldelumab 10 mg/kg arm); one serious 
AE of peripheral arterial thrombosis (in the eldelumab 10 mg/kg arm); and one 
serious AE of small intestinal obstruction (in the eldelumab 20 mg/kg arm).  
Patient demographics were generally well balanced between treatment groups 
(Table 1). Sixty-five percent of patients were recruited from Europe, the majority of 
whom were located in Eastern Europe. The mean duration of Crohn’s disease was 
9.1 years and the mean CDAI was 317. More than 70% of patients had previously 
received treatment with corticosteroids and/or immunosuppressants. Furthermore, 
63% of patients had previously received biologic therapy, and approximately 40% of 
patients overall had received treatment with ≥2 biologics. More patients in the 
eldelumab 10 mg/kg group had failed prior corticosteroids or immunosuppressants 
(80.0 and 85.0%, respectively) compared with patients in the eldelumab 20 mg/kg 
(75.6 and 68.3%) and placebo groups (62.5 and 72.5%). A higher percentage of 
patients in the eldelumab 10 mg/kg arm were receiving concomitant 
immunosuppressants (40.0%) compared with the eldelumab 20 mg/kg and placebo 
arms (17.1 and 27.5%, respectively). Eighty-one (66.9%) patients were included in 
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the endoscopy cohort. The baseline characteristics of the patients in the endoscopy 
cohort were generally similar to those in the overall patient population, with some 
exceptions: the mean baseline CDAI score was slightly lower across all treatment 
arms (range 295–308) compared with the overall population (range 310–323), and 
the proportion of patients who had received prior biologic therapy in the eldelumab 20 
mg/kg group was higher (73.9%) compared with the overall population (58.5%; Table 
1 and Supplementary Table 1). 
3.2. Primary endpoint 
The study did not meet its primary endpoint. Logistic regression analysis showed that 
there was no statistically significant exposure–remission relationship with eldelumab 
at Week 11 (OR [90% CI] 1.064 [0.958, 1.182]; Figure 1). Optimal exposure was 
reached with both eldelumab doses in this study and clinical efficacy was maximised. 
3.3. Clinical remission and response 
Small numerical but non-significant differences were seen at Week 11 between the 
placebo and active treatment arms in terms of the percentages of patients achieving 
CDAI remission and response (Figure 2a). Eldelumab 20 mg/kg resulted in the 
highest rates of CDAI remission, while treatment with eldelumab 10 mg/kg conferred 
the highest CDAI response rates (treatment differences versus placebo, 9 and 13%, 
respectively).  
 Higher rates of CDAI remission and response at Week 11 were reported for the 
subgroup of biologic-naïve patients treated with eldelumab 10 and 20 mg/kg 
compared with patients who received placebo (Figure 2b and c). Similarly, CDAI 
remission and response rates with eldelumab were lower in patients who had 
received prior biologic treatment compared with biologic-naïve patients (Figure 2b 
and c). 
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 CDAI reductions over time in eldelumab-treated patients were greater in biologic-
naïve patients compared with patients who had received previous treatment with 1–2 
biologics (Figure 2d). Reductions in CDAI scores in biologic-naive patients were 
particularly pronounced with eldelumab 10 mg/kg and separated from those in 
patients who were treated with placebo by Week 1. Differentiation in CDAI reductions 
between patients who were biologic naïve and treated with eldelumab 20 mg/kg and 
those who received placebo did not become evident until Week 5. CDAI changes 
with placebo were broadly similar over time regardless of whether patients had 
previously received biologics.  
3.4. Other endpoints 
In the endoscopy patient cohort (SES-CD >2 at baseline), treatment with eldelumab 
10 and 20 mg/kg resulted in greater mean reductions from baseline in SES-CD 
compared with placebo (–3.44, –3.57 and –0.94, respectively; Figure 3a). Higher 
proportions of patients treated with eldelumab 10 and 20 mg/kg versus placebo 
experienced ≥50% reductions in SES-CD (endoscopic response; Figure 3b).  
 In the endoscopy patient cohort, improvements in the SES-CD and the percentage 
of patients achieving ≥50% reduction in SES-CD with eldelumab were similar across 
the biologic-naïve and biologic-failure subgroups (Figure 3a and b). However, the 
endoscopy placebo response rates appeared to be greater in the biologic-naïve 
subgroup compared with patients who had previously received biologics. 
 Compared with placebo, a substantially higher percentage of patients in the 
eldelumab 10 and 20 mg/kg arms achieved the composite clinical and endoscopy 
endpoint (≥30% decrease in stool frequency and abdominal pain plus a 3-point 
decrease in SES-CD/SES-CD of zero; Figure 4). Composite placebo rates for both 
the biologic-naïve and biologic-failure subgroups were low (11.1% and 5.9%, 
respectively). Composite response rates were significantly higher in both of the 
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eldelumab treatment arms compared with placebo in the overall population as well as 
in the biologic-naïve and biologic-failure subgroups. The difference in response rates 
between the eldelumab treatment arms and the placebo arm was higher when 
assessed using the composite endpoint compared with either of the clinical or 
endoscopic endpoints alone. 
In the post hoc sensitivity analyses, using an increasingly more stringent requirement 
for the baseline endoscopic disease activity (total SES-CD ≥4 or ≥6, compared to>2) 
did not result in a greater effect size using various endoscopic and composite 
endpoints (Supplementary Table 2). 
 There was little difference between the treatment groups in terms of change in 
hsCRP or faecal calprotectin in this study. Mean (standard error [SE]) change from 
baseline in hsCRP at Week 11 was 4.6 (2.4), –3.6 (2.8) and 3.6 (4.0) mg/L in the 
eldelumab 10 and 20 mg/kg and placebo arms, respectively. Mean (SE) change in 
faecal calprotectin was –97.3 (130.6), –101.4 (88.2) and –100.7 (51.0) µg/g, 
respectively.  
3.5. Safety 
Safety data for the induction period are summarised in Table 2. Treatment-related 
AEs were experienced by 30.0% (12/40), 39.0% (16/41) and 17.5% (7/40) of patients 
in the eldelumab 10 and 20 mg/kg and placebo groups, respectively. Headache was 
the most commonly reported treatment-related AE overall, occurring in 2 patients 
(5%) in each group. Serious gastrointestinal AEs occurred in 2 patients in each 
group. Other serious AEs were hypersensitivity (2 patients in the eldelumab 20 mg/kg 
arm), viral gastroenteritis (1 patient in the eldelumab 20 mg/kg arm) and peripheral 
artery thrombosis (1 patient in the eldelumab 10 mg/kg arm). The majority of AEs 
were mild to moderate in intensity. 
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 A higher proportion of patients (35.0%) in the placebo group reported a system 
organ class AE of infection/infestations compared with the eldelumab 10 and 20 
mg/kg groups (22.5 and 26.8%, respectively).  
 Compared with the placebo group, more patients receiving eldelumab 10 and 20 
mg/kg experienced an infusion reaction (0/40 patients, 4/40 [10.0%] patients and 
11/41 [26.8%] patients, respectively). All of the infusion events in the eldelumab 10 
mg/kg arm were mild to moderate in intensity; three events of hypersensitivity in the 
eldelumab 20 mg/kg arm were severe (all observed before the protocol amendment).  
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4. Discussion 
This Phase IIa study explored the exposure–remission relationship of eldelumab in 
Crohn’s disease. The primary endpoint was not met as no significant exposure–
remission relationship was seen at Week 11, indicating that at the doses of 10 and 
20 mg/kg studied, clinical efficacy had been maximised. However, during the 
induction period, eldelumab demonstrated trends towards clinical activity in Crohn’s 
disease, particularly among patients who were biologic naïve. Because the primary 
endpoint was not met, these findings should be considered exploratory, despite the 
fact that the 90% CI did not cross zero.This observation is consistent with other 
recent Crohn’s disease studies in which clinical response was more robust in 
biologic-naïve versus biologic-failure populations.28-30 In this study, substantial 
treatment differences in terms of the rates of CDAI response and remission with 
eldelumab in biologic-naïve patients were driven by the greater clinical efficacy of 
eldelumab in this subgroup (in subanalyses of remission and response) but also by 
lower rates of placebo response in this subgroup (response subanalysis only). High 
placebo response rates have been seen previously in inflammatory bowel disease 
trials of biologic therapies31-33 and, as shown by the variable placebo response rates 
reported here, it is difficult to control for this phenomenon. While significant effort was 
expended on ensuring selection of patients with true inflammatory disease (via 
requirements for elevations in hsCRP, faecal calprotectin and/or endoscopic lesions), 
this study is the first to indicate that endpoint selection, in particular the use of a 
composite endpoint encompassing both clinical and endoscopic components, may 
also be effective for controlling placebo response rates. 
 This was the first placebo-controlled, prospective endoscopy study with central 
reading in patients with moderate to severely active Crohn’s disease and therefore 
substantially increases the current evidence base regarding the operational 
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characteristics of endoscopy scoring in this population. In contrast with the clinical 
findings, equal endoscopic activity was observed with eldelumab in both the biologic-
naïve patients and in patients who had received biologic treatment previously. The 
placebo endoscopic improvement in the biologic-naïve group appears to be higher 
than the biologic-failure group, in whom almost no endoscopic improvements were 
observed; this could be due to the natural waxing–waning of disease resulting in 
spontaneous mucosal improvement in the biologic-naïve group who, at baseline, had 
shorter disease duration and milder endoscopic disease. The present study was not 
powered to investigate the endoscopic endpoints or the subpopulation analyses 
statistically and therefore it is not possible to comment on the significance of our 
findings. Given that this is the first study to have used centrally read ileocolonoscopy 
in a mixed Crohn’s disease population comprising both patients who were biologic 
naïve and those who had previously been treated with biologics, confirmation of 
these endoscopic results requires further exploration in future studies. 
 Clinical symptoms and endoscopic activity in Crohn’s disease correlate only weakly 
and therefore it is perhaps not surprising that clinical and endoscopic response with 
eldelumab differ with regard to prior biologic use status.34 Given the lack of 
correlation between clinical and endoscopic endpoints, a composite endpoint 
requiring both clinical and endoscopic improvement in a given patient may be a 
better indicator of therapeutic effectiveness.23 In the post hoc composite endpoint 
analysis conducted here, a patient was considered a responder only if a 30% 
improvement in clinical symptoms (abdominal pain and stool frequency) was 
accompanied by a 3-point decrease in SES-CD score or an absolute SES-CD score 
of zero. In this analysis, significant treatment differences between eldelumab and 
placebo were observed in both the biologic-naïve and biologic-failure subgroups, with 
very low placebo response rates in both populations. Subgroup analysis by baseline 
SES-CD score in the endoscopy cohort (baseline SES-CD >2) yielded similar results. 
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Future studies in patients with Crohn’s disease with centrally read endoscopy should 
further examine the validity of this approach. 
 In an effort to assess whether the severity of endoscopic disease activity at 
baseline might affect the observed treatment size, subgroup analyses with increasing 
baseline total SES-CD score were conducted. Baseline SES-CD scores of >2, ≥4 or 
≥6 did not appear to have a significant impact on the observed effect size of change 
in SES-CD, endoscopic response as defined by 50% decrease in SES-CD, or an 
endoscopic and clinical composite endpoint. These exploratory observations should 
be confirmed in future studies with a larger sample size.   
 No new safety signals were observed with eldelumab. Most AE-led discontinuations 
with eldelumab were due to infusion reactions, the frequency and severity of which 
diminished after extension of the infusion period from 90 minutes to 3 hours following 
a protocol amendment. The occurrence of infections was not increased with 
eldelumab compared with placebo. 
 In conclusion, clinical efficacy for eldelumab was maximised at the study doses of 
10 and 20 mg/kg; however, the primary endpoint of the trial was not achieved. 
Clinical response and remission with eldelumab were more pronounced in subgroups 
of patients who were biologic naïve, while endoscopic improvements with eldelumab 
were similar across the biologic-naïve and biologic-failure subgroups. Composite 
endpoints comprising both clinical and endoscopic scores provided the most robust 
discrimination between both eldelumab doses and placebo. Safety signals were 
consistent with those reported previously for eldelumab. 
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Table 1. Baseline demographics and clinical characteristics. 
Characteristic 
Placebo 
(n = 40) 
Eldelumab 
10 mg/kg  
(n = 40) 
Eldelumab  
20 mg/kg  
(n = 41) 
Total 
(N = 121) 
Mean age (SD), years 37.3 (13.1) 35.8 (13.0) 35.4 (13.1) 36.2 (13.0) 
Mean weight (SD), kg 69.6 (19.4) 75.1 (22.8) 70.2 (14.0) 71.6 (19.0) 
Female, n (%) 22 (55.0) 17 (42.5) 21 (51.2) 60 (49.6) 
Geographic region, n (%) 
 North America 
 Europe 
  Eastern Europe 
  Western Europe 
 South Africa 
 
11 (27.5) 
28 (70.0) 
14 (35.0) 
14 (35.0) 
1 (2.5) 
 
12 (30.0) 
26 (65.0) 
18 (45.0) 
8 (20.0) 
2 (5.0) 
 
13 (31.7) 
25 (61.0) 
16 (39.0) 
9 (22.0) 
3 (7.3) 
 
36 (29.8) 
79 (65.3) 
48 (39.7) 
31 (25.6) 
6 (5.0) 
Mean (SD) duration of CD, years 9.5 (8.8) 8.7 (8.4) 9.3 (8.3) 9.1 (8.5) 
Mean (SD) CDAI score 323 (67) 310 (59) 317 (57) 317 (61) 
Prior therapy, n (%) 
 Corticosteroids 
 Immunosuppressants 
 Biologic 
  1–2 biologics 
  ≥3 biologics 
 
25 (62.5) 
29 (72.5) 
27 (67.5) 
22 (55.0) 
5 (12.5) 
 
32 (80.0) 
34 (85.0) 
25 (62.5) 
21 (52.5) 
4 (10.0) 
 
31 (75.6) 
28 (68.3) 
24 (58.5) 
21 (51.2) 
3 (7.3) 
 
88 (72.7) 
91 (75.2) 
76 (62.8) 
64 (52.9) 
12 (9.9) 
Concomitant corticosteroid, n (%) 
 Mean oral dose (mg/day) 
 Mean budesonide dose (mg/day) 
22 (55.0) 
23.1 
7.5 
21 (52.5) 
22.9 
8.1 
19 (46.3) 
23.1 
9.0 
62 (51.2) 
23.0 
8.2 
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Concomitant immunosuppressant, 
n (%) 
11 (27.5) 16 (40.0) 7 (17.1) 34 (28.1) 
Mean faecal calprotectin, µg/g (SD) 647.0 (571.3)  564.0 (678.8) 505.6 (388.8) 571.7 (556.4) 
Mean serum hsCRP, mg/L (SD) 23.4 (26.8) 13.8 (19.8) 15.0 (23.2) 17.4 (23.6) 
 
CD, Crohn’s disease; CDAI, Crohn’s Disease Activity Index; hsCRP, high-sensitivity C-reactive 
protein SD, standard deviation.
31 
 
 
Table 2. Overall summary of adverse events. 
Safety parameter 
Number (%) of patients  
Placebo 
(n = 40) 
Eldelumab 
10 mg/kg  
(n = 40) 
Eldelumab 
20 mg/kg  
(n = 41) 
Deaths 0 0 0 
SAEs 
 Treatment-related SAEs 
2 (5.0) 
0 
3 (7.5) 
1 (2.5) 
4 (9.8) 
3 (7.3) 
AEs 
 Treatment-related AEs 
 AEs resulting in discontinuation 
 Infections and infestations 
 Acute infusion reactions
a
 
31 (77.5) 
7 (17.5) 
0 
14 (35.0) 
0 
26 (65.0) 
12 (30.0) 
5 (12.5) 
9 (22.5) 
4 (10.0)
b
 
24 (58.5) 
16 (39.0) 
5 (12.2) 
11 (26.8) 
11 (26.8)
c
 
a
Potentially infusion-related AEs occurring from the start of study drug infusion until 1 hour 
after the end of infusion; 
b
all events were mild to moderate; 
c
3 events of ‘hypersensitivity’ 
were severe, all observed prior to protocol amendment. 
AE, adverse event; SAE, serious adverse event. 
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Figure 1 Exposure–remission analysis 
 
 
The average trough concentration is based on mean of Days 36, 50, and 78. Steady state 
was reached at Day 36. The flat black line denotes the clinical remission rate for all placebo 
subjects at Week 11. Probability of clinical remission, 90% CI bands, and odds ratio are 
based on model with log2-transformed trough data 
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Figure 2(A) Week 11 clinical remission and response. (B) Clinical remission by prior biologic use status. (C) Clinical response by prior biologic 
use status. (D) CDAI change over time according to prior biologic use. CI, confidence interval; CDAI, Crohn’s Disease Activity Index. 
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Figure 3 (A) Change from baseline in Simplified Endoscopic Score for Crohn’s 
disease. (B) Percentage of patients with ≥50% decrease from baseline in 
Simplified Endoscopic Score for Crohn’s disease. SD, standard deviation; SES-
CD, Simplified Endoscopic Score for Crohn’s disease. CI, confidence interval; SES-
CD, Simplified Endoscopic Score for Crohn’s disease. 
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Figure 4 Proportion of patients achieving composite response.*  
*Defined as ≥30% decrease in stool frequency and abdominal pain plus a 3-point 
decrease in SES-CD or an SES-CD of 0. Population included all patients with SES-
CD >2 at baseline with a post-baseline endoscopy score. 
SES-CD, Simplified Endoscopic Score for Crohn’s Disease. 
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Supplementary Table 1. Baseline demographics and clinical characteristics for patients (n = 
81) with both a baseline SES-CD score >2 and a follow-up SES-CD score 
 
Characteristic 
Placebo 
(n = 31) 
Eldelumab 
10 mg/kg  
(n = 27) 
Eldelumab  
20 mg/kg  
(n = 23) 
Mean age (SD), years 36.8 (13.9) 35.3 (13.3) 34.9 (12.0) 
Mean age ≥65 years, n (%) 1 (3.2) 0 (0.0) 0 (0.0) 
Mean weight (SD), kg 75.0 (27.3) 98.5 (61.5) 88.2 (49.9) 
Female, n (%) 16 (51.6) 10 (37.0) 14 (60.9) 
Race, white, n (%) 29 (93.6) 24 (88.9) 22 (95.7) 
Mean (SD) CDAI score 308 (72) 295 (57) 302 (65) 
Anti-TNF inadequate responder, n (%) 20 (64.5) 17 (63.0) 17 (73.9) 
CDAI, Crohn’s Disease Activity Index; SD, standard deviation; TNF, tumour necrosis factor 
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Supplementary Table 2. Post hoc analyses of patients with both a baseline SES-CD score 
>2 and a follow-up SES-CD score at Week 11 (n = 81) 
 
Post hoc analysis 
Placebo 
(n = 31) 
Eldelumab 
10 mg/kg 
(n = 27) 
Eldelumab 
20 mg/kg 
(n = 23) 
Mean (SD) change from baseline SES-
CD for patients [n] with: 
Baseline SES-CD >2 
 
Baseline SES-CD ≥4 
  
Baseline SES-CD ≥6  
 
 
-0.94 (4.87) 
[31] 
-0.06 (4.45) 
[31] 
0.00 (4.57) 
[29] 
 
 
-3.44 (5.32) 
[27] 
-3.58 (5.38) 
[26] 
-3.67 (5.58) 
[24] 
 
 
-3.57 (5.98) 
[23] 
-3.62 (6.27) 
[21] 
-4.32 (6.11) 
[19] 
% Patients (n/N) with ≥30% decrease in 
both liquid stools and abdominal pain 
and either a decrease from baseline 
SES-CD ≥3 or a SES-CD score of 0 for 
patients with: 
Baseline SES-CD >2 
Baseline SES-CD ≥4 
Baseline SES-CD ≥6 
 
 
 
 
 
6.5 (2/31) 
6.5 (2/31) 
6.9 (2/29) 
 
 
 
 
 
37.0 (10/27) 
38.5 (10/26) 
41.7 (10/24) 
 
 
 
 
 
30.4 (7/23) 
33.3 (7/21) 
36.8 (7/19) 
% Patients (n/N) with 50% decrease 
from baseline SES-CD for patients with: 
Baseline SES-CD >2 
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Baseline SES-CD ≥4 
Baseline SES-CD ≥6 
6.5 (2/31) 
6.5 (2/31) 
6.9 (2/29) 
29.6 (8/27) 
30.8 (8/26) 
29.2 (7/24) 
26.1 (6/23) 
19.1 (4/21) 
21.1 (4/19) 
SD, standard deviation; SES-CD, Simplified Endoscopic Score for Crohn’s Disease;  
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Supplementary Figure 1. Study design  
 
ASA, aminosalicylate; AZA, azathioprine; CDAI, Crohn’s Disease Activity Index; IV, intravenous; MP, mercaptopurine; MTX, methotrexate.  
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Supplementary Figure 2. Flow chart of patient disposition in the study  
 
